Preview Mode Links will not work in preview mode
Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape.  Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes  Value-based healthcare  Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials  Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.

Apr 28, 2025

Jaya Tiwari, Senior Vice President of Clinical and Regulatory Affairs at XVIVO, which is focused on improving organ preservation for transplantation. Current organ preservation methods using ice coolers limit the time and distance organs can be transported.  XVIVO's perfusion technology can significantly extend the preservation time of hearts, kidneys, livers, and lungs, providing hospitals and transplant centers access to more viable organs. The company is passionate about increasing organ availability to give more patients access to life-saving transplants.

Jaya explains, "I take it back to 1967 when the first heart transplant was performed in Cape Town, and the way that the heart was preserved and transported in essentially an ice box. The standard of care for the preservation of organs is still an ice or an ice cooler with ice. So, this decreases metabolic activities. So, to try to preserve the organs so that you can get them from the donor to the recipient, the problem is that the organs are not viable for a very long time, and they start to degrade very quickly. That really limits the amount of time that the organs can be on ice, transported from the donor to the recipient hospital. Because of that logistical complexity, a lot of organs are ultimately not transplanted."

"There have been some preclinical studies that we've done that have shown viability of the heart tissue for up to 24 hours. But what I think is probably the most remarkable example that we've seen is that the universities in Paris have put together something called an investigator-initiated study, where they actually were able to transport a donor heart from the French West Indies to Paris for transplant. That was about 12 hours that the heart was in transport and using the device. So that's remarkable because that essentially tripled the standard preservation time for hearts. Now, in the US, we have a clinical trial where we're currently seeking approval from the FDA that it's safe and effective to use this device for up to 12 hours."

#XVIVO #HealthcareInnovation #LifeSavingTechnology #PatientOutcomes #OrganTransplantation #OrganTransplants

xvivogroup.com

Listen to the podcast here

XVIVO